GLP-1 Side Effects

Summary: Most GLP-1 side effects are gastrointestinal, dose-dependent, and fade after the first few weeks; the rare-but-serious effects are pancreatitis, gallbladder disease, kidney injury from dehydration, and worsening diabetic retinopathy.

This content is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before starting, changing, or stopping any medication.

The short answer: roughly 40 to 45 percent of people on a GLP-1 will get nausea, 15 to 25 percent will get vomiting or diarrhea, and another 20 to 25 percent will get constipation. Almost all of it happens during dose escalation and almost all of it fades. The rare-but-serious effects, pancreatitis, gallbladder disease, acute kidney injury from dehydration, and worsening diabetic retinopathy, sit in the single-digit-per-1000 range but are the reason you call a doctor instead of riding it out.

This page is the class-wide picture. Semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound), liraglutide (Victoza, Saxenda), and dulaglutide (Trulicity) share most of their side effect profile. The differences between them are mostly differences in degree, not in kind.

The numbers from the pivotal trials

The STEP-1 trial enrolled 1961 adults with obesity on semaglutide 2.4 mg weekly. SURMOUNT-1 enrolled 2539 adults with obesity on tirzepatide at 5, 10, or 15 mg weekly. The FDA approved Wegovy on STEP-1 and approved Zepbound on SURMOUNT-1. Both trials reported side effects in detail, which is why we have reliable percentages instead of guesses.

The placebo column matters. Roughly 10 percent of people in any obesity trial report nausea even on saline, because they are eating differently, being weighed weekly, and paying attention to their bodies in a way they were not before. The signal in the GLP-1 column is the gap above placebo.

The GI cluster: nausea, vomiting, diarrhea, constipation

The mechanism that drives weight loss is the same mechanism that drives the GI side effects. GLP-1 receptor agonists slow gastric emptying, dampen the appetite-related signals in the brainstem, and shift gut motility. Slowed gastric emptying means food sits longer, which is why you feel full earlier and why a normal-sized meal can trigger reflux or vomiting that the same meal would not have triggered before.

Nausea

Most common, peaks during the first two dose steps, fades within two to four weeks at each new dose. The clinical pattern: you titrate up on Sunday, you feel queasy Monday and Tuesday, you adapt by Friday, and the next four weeks are easier. Then you step up again and the cycle repeats. By the time you reach maintenance dose, most people no longer notice it.

Fixes that work: smaller meals, eat slowly, stop eating before you feel full, avoid high-fat and high-sugar meals during titration weeks, sip water throughout the day rather than chugging it during meals. Ginger tea and bland carbohydrates help some people. If nausea is severe, prescribers will sometimes write for ondansetron 4 mg as needed.

Vomiting

A subset of nausea cases progress to vomiting. The trigger is usually the same: a meal that was too large, too rich, or too late. Vomiting that happens once after a heavy meal is a tolerance problem. Vomiting that happens every day for a week, especially with severe abdominal pain, is not a tolerance problem and is the reason to call your prescriber. Persistent vomiting can dehydrate you fast enough to cause acute kidney injury, and on the obstruction end of the spectrum can mask gastroparesis or bowel obstruction.

Diarrhea

About 20 to 30 percent of users in the trials. Often resolves within a few weeks. Hydrate. Cut back on coffee, alcohol, and dairy temporarily. Loperamide works for short-term relief if needed. Persistent diarrhea past a month should be reported to your prescriber to rule out unrelated causes.

Constipation

The other side of the same coin. Slowed gastric emptying and reduced food intake mean less bulk moving through the colon. Roughly one in four users reports constipation, especially on semaglutide. Increase soluble fiber (psyllium works well), drink more water, walk daily, and use a stool softener or osmotic laxative like polyethylene glycol if needed.

Injection site reactions

Mild redness, itching, or a small lump at the injection site is common and rarely serious. The FDA labels for Wegovy and Ozempic list injection site reactions at 1 to 3 percent of users ^[1][2]. Rotating sites between weekly doses (abdomen, thigh, upper outer arm) prevents the same patch of subcutaneous tissue from getting repeatedly irritated. Letting refrigerated medication warm to room temperature for a few minutes before injecting reduces the sting and reduces local skin reactions.

True allergic reactions are rare but possible. Hives, widespread itching, swelling around the lips or throat, or trouble breathing after an injection is anaphylaxis and is a 911 call. Stop the medication and seek emergency care.

Fatigue and headache

Both show up in the first few weeks. Fatigue is partially a side effect of the medication and partially a side effect of eating significantly less. If you drop from 2200 calories per day to 1400 calories per day in the same week, you will feel tired even if the drug had no direct effect. Hydration, adequate protein (aim for 1.2 to 1.6 g/kg of body weight), and not skipping meals all help. Headache responds to the usual measures and tends to fade after the first two to four weeks of treatment.

Rare but serious: what to actually watch for

This is the section to read once and remember. The class-wide labels for Wegovy, Ozempic, Mounjaro, and Zepbound all list the same set of serious risks ^[1][2][3]. Most are uncommon. None should be ignored when they happen.

Pancreatitis

Acute pancreatitis has been reported in roughly 0.1 to 0.3 events per 100 patient-years on GLP-1 therapy. That is rare, but the consequences are not. The presenting symptom is severe upper abdominal pain that often radiates to the back, frequently with nausea and vomiting that does not resolve. If you get that pain, stop the medication and go to an emergency department. The diagnosis is made with lipase and imaging, not by guessing. People with a history of pancreatitis, heavy alcohol use, or very high triglycerides are at higher baseline risk and should discuss this before starting.

Gallbladder disease

GLP-1 medications increase the risk of gallstones and cholecystitis, mostly because rapid weight loss does. Pooled analyses suggest a 25 to 70 percent relative risk increase, which works out to about 1 to 3 additional events per 1000 patient-years. The mechanism: weight loss thickens bile and slows gallbladder emptying, which lets stones form. Risk is highest in the first 12 to 24 months when weight loss is fastest. Red flag symptoms are pain in the upper right abdomen, fever, nausea after fatty meals, or yellowing of the skin or eyes. Call your prescriber if any of these appear.

Thyroid C-cell tumor warning

Every GLP-1 receptor agonist in the US carries a boxed warning about thyroid C-cell tumors. The warning exists because in rat studies, dose-dependent C-cell hyperplasia and medullary thyroid carcinoma were observed. In humans, more than 15 years of liraglutide and semaglutide data and 5+ years of tirzepatide data have not confirmed an increased rate of medullary thyroid cancer above the background population rate. Medullary thyroid cancer is rare in the general population, about 1 in 30,000 to 40,000 adults. The black box exists out of caution and because the rat data is real, but the human signal has not materialized despite millions of treated patients.

Acute kidney injury from dehydration

The kidney risk is not direct toxicity. It is a downstream consequence of vomiting and diarrhea. People who get severe GI side effects, do not replace fluids, and continue on medication or other kidney-affecting drugs (ACE inhibitors, ARBs, NSAIDs, diuretics) can develop acute kidney injury that lands them in the hospital. The fix is mostly prevention: hydrate aggressively if you are vomiting or have diarrhea, and call your prescriber if you cannot keep fluids down for 24 hours. Pre-existing kidney disease raises the stakes and warrants closer monitoring during titration.

Diabetic retinopathy worsening

In the SUSTAIN-6 trial of semaglutide, 3.0 percent of treated patients experienced retinopathy complications versus 1.8 percent on placebo. The mechanism is the same one that causes transient retinopathy worsening with insulin: rapid improvement in blood sugar can briefly destabilize existing retinopathy before things settle. People with moderate to severe pre-existing diabetic retinopathy should have a baseline eye exam, then follow-up exams during the first year of treatment. People without diabetic retinopathy are not at meaningful risk.

Allergic reactions

Mild skin reactions are common. True anaphylaxis is rare. Hives, throat swelling, difficulty breathing, or a sudden drop in blood pressure after an injection requires emergency care. Some people develop antibodies to specific GLP-1 medications, particularly exenatide, which can reduce effectiveness over time and occasionally cause persistent injection site issues.

FDA suicidal ideation surveillance: null findings

In 2023 the FDA opened an investigation into reports of suicidal thoughts in people taking GLP-1 medications, prompted by post-marketing reports and a European inquiry. In January 2024 the FDA published interim findings: the available data did not show a causal link between GLP-1 use and suicidal ideation. A larger analysis published in 2024 of roughly 240,000 patients found no increased risk versus matched controls. The European Medicines Agency reached the same conclusion in April 2024. The current FDA position, repeated through 2026, is that no causal association has been established. The label has not been updated to add a suicide warning.

That does not mean to ignore mental health changes. If you develop new depression, persistent low mood, or thoughts of self-harm while on a GLP-1, report it. The data does not support a class effect, but rare idiosyncratic responses happen and usually resolve after dose reduction or discontinuation.

Reversible versus persistent

Almost everything on this list resolves when the medication is stopped or reduced.

Weight regain after stopping is the most predictable reversal. STEP-1 extension data showed that participants regained roughly two-thirds of lost weight within a year of discontinuation ^[4]. That is not a side effect in the pharmacologic sense, but it is the most common practical consequence of stopping the drug.

Dose management strategies

The single biggest determinant of how rough the side effects feel is how fast you titrate. Both Lilly and Novo Nordisk built four-week steps into the approved schedules for a reason. Every dose step doubles the GLP-1 receptor stimulation, and the gut needs time to adapt.

If side effects are bad at a given dose, the answer is almost never to push through to the next dose. The answer is to hold at the current dose for an extra four weeks, then re-attempt the step up. If side effects return immediately at the higher dose, drop back down. Many people get the same long-term weight loss results on lower maintenance doses with slower titration than they would have gotten on the standard schedule with frequent vomiting.

Stop the medication entirely and call your prescriber for: severe abdominal pain (especially radiating to the back), inability to keep fluids down for 24 hours, signs of dehydration (dark urine, dizziness on standing, no urination), fever with right upper abdominal pain, sudden vision changes, signs of allergic reaction, or any new neck mass, hoarseness, or trouble swallowing.

Which GLP-1 has the fewest side effects?

Tirzepatide produces somewhat lower rates of nausea and vomiting than semaglutide at comparable weight-loss efficacy. The dual GIP/GLP-1 mechanism appears to partially offset the GI signaling that GLP-1 alone drives. In SURMOUNT-1, tirzepatide 15 mg had 29.6 percent nausea versus STEP-1's 44.2 percent for semaglutide 2.4 mg ^[4][5]. Dulaglutide and weekly exenatide have lower rates of severe GI side effects but also produce less weight loss. There is no GLP-1 with zero side effects. There are slower titrations, smaller doses, and better dietary habits that make the side effects livable.

What about weight loss injection side effects from telehealth brands?

Found, Calibrate, Hims, Ro, Synergy Rx, and BreezeMeds dispense the same FDA-approved or compounded GLP-1 medications discussed above. The side effects are the same because the molecules are the same. The variables that matter are the actual medication you receive, the dose, and the titration schedule, not the brand of the telehealth wrapper. Compounded semaglutide and compounded tirzepatide produce the same side effect profile as the brand products when dosed correctly. If a telehealth provider escalates you faster than the FDA-approved schedule to hit a weight-loss target faster, expect harder side effects.

Long-term safety

Five years into widespread GLP-1 use for obesity and 15+ years for diabetes, no new class-wide signal has emerged that was not visible in the pivotal trials. The gallbladder and pancreatitis risks were known. The retinopathy signal was known. The thyroid warning is unchanged. The mental health surveillance has not produced a causal link. Cardiovascular outcomes have been net-positive in the major trials (SUSTAIN-6, SELECT, LEADER), with reductions in heart attack and stroke in high-risk populations.

The unanswered questions are mostly about very long-term use: what happens at year ten, year fifteen, year twenty on continuous GLP-1 therapy. The honest answer is that the registries are still maturing. The signals available so far are reassuring, but they are not the same as decades of follow-up.

Common questions about GLP-1 side effects

How long do GLP-1 side effects last?

Most GI side effects peak within the first week of a new dose and resolve within two to four weeks as the body adapts. Persistent side effects past three months are less common and worth reporting to your prescriber.

What are the most common long-term side effects of GLP-1 medications?

Persistent mild GI symptoms in a minority of users, gallbladder disease in roughly 1 to 3 per 1000 patient-years, and weight regain after discontinuation. Long-term cancer signals, including thyroid cancer, have not been confirmed in human data despite 15+ years of follow-up for some agents.

Is there a real long-term cancer risk from GLP-1 medications?

Rat studies showed thyroid C-cell tumors, which is why every label carries a boxed warning. Human registry data through 2025 has not confirmed an increased rate of medullary thyroid cancer or other malignancies above the background population rate. People with a personal or family history of medullary thyroid cancer or MEN 2 should not use GLP-1 agents.

How do I manage GLP-1 side effects during dose titration?

Eat smaller meals, hydrate aggressively, avoid high-fat foods during titration weeks, and hold at the current dose for an extra four weeks if symptoms are severe. Do not push through if you cannot keep food or fluids down.

Which GLP-1 has the fewest side effects?

Tirzepatide has lower rates of nausea and vomiting than semaglutide at comparable efficacy. Dulaglutide and weekly exenatide have milder GI profiles but produce less weight loss. No GLP-1 has zero side effects.

Should I keep a symptom diary or use a side effect tracker app?

A simple daily log of symptoms, severity, and meal timing is genuinely useful during the first three months. It helps you and your prescriber spot patterns, distinguish drug effects from dietary triggers, and decide whether to titrate, hold, or stop. A notebook or phone notes work fine; the app is optional.

Can I get pancreatitis from GLP-1 medications?

Acute pancreatitis is rare, occurring at roughly 0.1 to 0.3 events per 100 patient-years. Severe persistent upper abdominal pain radiating to the back is the warning sign. Stop the medication and seek emergency care if it happens. People with prior pancreatitis or heavy alcohol use are at higher baseline risk.

Do GLP-1 medications cause depression or suicidal thoughts?

The FDA investigated suicidal ideation reports in 2023 and 2024 and found no causal link in the available data. The European Medicines Agency reached the same conclusion. Idiosyncratic mood changes have been reported in some users and typically resolve with dose reduction or discontinuation.

How do GLP-1 medications affect the kidneys?

GLP-1 drugs do not directly damage kidneys. Acute kidney injury can occur indirectly if severe vomiting or diarrhea cause dehydration. Hydration during episodes of GI side effects is the main protection. People with existing kidney disease need closer monitoring during titration.

What injection site reactions are normal?

Mild redness, itching, or a small lump that resolves within a few days is common and not dangerous. Rotate injection sites weekly between abdomen, thigh, and upper outer arm. Widespread hives, swelling away from the injection site, or breathing difficulty is anaphylaxis and requires emergency care.